(SIX: SFZN) The Siegfried Group announces the acquisition of the drug product manufacturing facility together with all related employees and contracts from Arena Pharmaceuticals GmbH in Zofingen, Switzerland. Subject to certain customary closing conditions, the transaction is expected to close around March 31, 2018.
Since the acquisition of the facility from Siegfried in 2007, Arena has been manufacturing its own pharmaceutical drug product Belviq in Zofingen, and, in addition, has provided contract manufacturing services to Siegfried and other third parties. Arena has now decided to divest its manufacturing facility in Zofingen.
Together with the real estate, fixtures, equipment and other assets needed for the operation of the manufacturing facility, all Arena employees and business contracts will be taken over by Siegfried. Siegfried will continue to operate the facility in Zofingen and integrate it into its existing drug products manufacturing organization.
Peter A. Gehler, Chief Communications Officer
Tel. +41 62 746 11 48
Cell +41 79 416 4116
Siegfried Holding AG
Untere Brühlstrasse 4
The Siegfried Group is active worldwide in the field of Life Sciences with production facilities located in Switzerland, the USA, Malta, China, Germany and France. At the end of 2016, Siegfried reported annual sales of CHF 718 million and employs at the time being approximately 2300 employees at nine locations on three continents. Siegfried Holding AG is listed on the Swiss Exchange (SIX: SFZN).
Siegfried is active in both the primary and secondary production of drugs. The company develops and manufactures active pharmaceutical ingredients for the research-based pharmaceutical industry as well as the corresponding intermediates and controlled substances, and provides development and production services for finished dosage forms including sterile filling.